Abstract:
Data to be part of a planned US FDA filing in H2 2025
PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee
Published: 28 May 2025 by GSK press release
Select a country to view results for that country.
Select All (Default)
Algeria
Angola
Ascension Island (UK)
Benin
Botswana
Burkina Faso
Burundi
Cabo Verde (Cape Verde)
Cameroon
Canary Islands (Spain)
Central African Republic
Ceuta (Spain)
Chad
Comoros
Congo: Democratic Republic of Congo (DRC)
Congo: Republic of Congo (Congo-Brazzaville)
Côte d'Ivoire (Ivory Coast)
Djibouti
Egypt
Equatorial Guinea
Eritrea
Eswatini
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Libya
Madagascar
Madeira (Portugal)
Malawi
Mali
Mauritania
Mauritius
Mayotte (France)
Melilla (Spain)
Morocco
Mozambique
Namibia
Niger
Nigeria
Pelagie Islands (Italy)
Réunion (France)
Rwanda
Saint Helena (UK)
São Tomé and Príncipe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
South Sudan
Sudan
Tanzania
Togo
Tristan da Cunha (UK)
Tunisia
Uganda
Western Sahara and Sahrawi Arab Democratic Republic
Zambia
Zimbabwe
Published: 28 May 2025 by GSK press release
Copyright © Therapists Africa 2025
